Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series
Immune checkpoint inhibitors (ICIs) have revolutionized cancer care; however, they are associated with ICI-related adverse events (ICI-AEs). Polyarthritis is a rare ICI-AE. Here we describe 2 patient cases of ICI-induced polyarthritis, induced by nivolumab/ipilimumab and sasanlimab for melanoma and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2023-01-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2022.0815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850182801813405696 |
|---|---|
| author | Megan Smith-Uffen Konstantinos Tselios |
| author_facet | Megan Smith-Uffen Konstantinos Tselios |
| author_sort | Megan Smith-Uffen |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have revolutionized cancer care; however, they are associated with ICI-related adverse events (ICI-AEs). Polyarthritis is a rare ICI-AE. Here we describe 2 patient cases of ICI-induced polyarthritis, induced by nivolumab/ipilimumab and sasanlimab for melanoma and urothelial cancer, respectively. Both patients had a medical history of nonrheumatological autoimmune disease, developed symptoms within 8 weeks of ICI, and had negative autoantibodies. Symptoms resolved with glucocorticoids. Neither patient discontinued their anticancer therapy. These cases add to the literature on ICI-induced polyarthritis. As ICIs become the standard of care, clinicians should familiarize themselves with their adverse effects. |
| format | Article |
| id | doaj-art-a183a53882fc48ae85b82b99a8a6b484 |
| institution | OA Journals |
| issn | 2767-7664 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | American College of Physicians |
| record_format | Article |
| series | Annals of Internal Medicine: Clinical Cases |
| spelling | doaj-art-a183a53882fc48ae85b82b99a8a6b4842025-08-20T02:17:33ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642023-01-012110.7326/aimcc.2022.0815Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case SeriesMegan Smith-Uffen0Konstantinos Tselios11Internal Medicine Residency Program, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada2Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, CanadaImmune checkpoint inhibitors (ICIs) have revolutionized cancer care; however, they are associated with ICI-related adverse events (ICI-AEs). Polyarthritis is a rare ICI-AE. Here we describe 2 patient cases of ICI-induced polyarthritis, induced by nivolumab/ipilimumab and sasanlimab for melanoma and urothelial cancer, respectively. Both patients had a medical history of nonrheumatological autoimmune disease, developed symptoms within 8 weeks of ICI, and had negative autoantibodies. Symptoms resolved with glucocorticoids. Neither patient discontinued their anticancer therapy. These cases add to the literature on ICI-induced polyarthritis. As ICIs become the standard of care, clinicians should familiarize themselves with their adverse effects.https://www.acpjournals.org/doi/10.7326/aimcc.2022.0815 |
| spellingShingle | Megan Smith-Uffen Konstantinos Tselios Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series Annals of Internal Medicine: Clinical Cases |
| title | Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series |
| title_full | Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series |
| title_fullStr | Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series |
| title_full_unstemmed | Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series |
| title_short | Immune Checkpoint Inhibitor-Induced Polyarthritis: A Case Series |
| title_sort | immune checkpoint inhibitor induced polyarthritis a case series |
| url | https://www.acpjournals.org/doi/10.7326/aimcc.2022.0815 |
| work_keys_str_mv | AT megansmithuffen immunecheckpointinhibitorinducedpolyarthritisacaseseries AT konstantinostselios immunecheckpointinhibitorinducedpolyarthritisacaseseries |